Fan, R., Li, X., Gu, X., Chan, J
Tirzepatide is a dual GLP-1/GIP agonist that helps in controlling glucose and obesity management
Take a glance around our waiting room or apothecary to see what a patient population engaged in maintaining good health actually looks like
Executive Summary Quick Insight: The GLP-1 Weight Loss Drug Market is on track to more than double to USD 192 billion by 2035 , driven by explosive patient demand for injectable and oral incretin therapies, multi-indication label expansion beyond obesity into cardiovascular protection and metabolic disease management, a robust late-stage pipeline of next-generation triple agonists, and unprecedented payer engagement transforming obesity into a fully reimbursable chronic disease requiring long-term pharmacological management
Form and Administration Oral Semaglutide is taken once daily as a pill ideal for patients who prefer not to use injections